<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767793</url>
  </required_header>
  <id_info>
    <org_study_id>P08650</org_study_id>
    <secondary_id>037-101</secondary_id>
    <nct_id>NCT00767793</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS117548 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of INS117548 ophthalmic
      solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of discontinuation</measure>
    <time_frame>15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in: &gt;Ophthalmic exam parameters &gt;Corneal thickness &gt;Intraocular pressure &gt;Visual Acuity &gt;Physical exam, vital signs and laboratory parameters</measure>
    <time_frame>15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance</measure>
    <time_frame>15</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in each eye every 12 hours for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One drop in each eye every 12 hours for seven days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS117548</intervention_name>
    <description>One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS117548</intervention_name>
    <description>One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS117548</intervention_name>
    <description>One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma

          -  Have best corrected visual acuity in both eyes of at least +0.5 or better

        Exclusion Criteria:

          -  Are diagnosed with closed angle glaucoma, exfoliation syndrome or exfoliation
             glaucoma, and pigment dispersion or secondary glaucoma

          -  Have a history of any type of intraocular surgery, except for cataract surgery

          -  Have had cataract surgery within three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Haque, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor, Inspire</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

